JADPRO Live 2023

Blood Cancers Today covers updates in hematologic malignancies at JADPRO Live 2023, including myeloma news.

Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.

Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.

$Pooled Analysis Shows Elranatamab ‘Effective’ in Relapsed, Refractory Myeloma$

Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.

Getting the right care team, treatment, and testing are three steps to empower patients with MM.